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Background: Epidermal growth factor (EGF) 
activates EGF receptor (EGFR) to promote cell 
migration and cancer. 
Results: EGF/EGFR upregulates the cell surface 
glycoprotein CDCP1 and blockade of CDCP1 
reduces EGF/EGFR-induced migration of ovarian 
cancer cells lines. CDCP1 is expressed by ovarian 
tumors. 
Conclusion: CDCP1 contributes to EGF/EGFR-
induced cell migration. 
Significance: Targeting of CDCP1 may be a 
rational approach to inhibit cancers mediated by 
EGFR. 
 
Epidermal growth factor (EGF) activation of 
the EGF receptor (EGFR) is an important 
mediator of cell migration and aberrant 
signaling via this system promotes a number of 
malignancies including ovarian cancer. We 
have identified the cell surface glycoprotein 
CDCP1 as a key regulator of EGF/EGFR-
induced cell migration. We show that signaling 
via EGF/EGFR induces migration of ovarian 
cancer Caov3 and OVCA420 cells with 
concomitant upregulation of CDCP1 mRNA 
and protein. Consistent with a role in cell 
migration CDCP1 relocates from cell-cell 
junctions to punctate structures on filopodia 
following activation of EGFR. Significantly, 
disruption of CDCP1, either by silencing or the 
use of a function blocking antibody, efficiently 
reduces EGF/EGFR-induced cell migration of 
Caov3 and OVCA420 cells. We also show that 
upregulation of CDCP1 is inhibited by 
pharmacological agents blocking ERK but not 
Src signaling indicating that the 
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RAS/RAF/MEK/ERK pathway is required 
downstream of EGF/EGFR to induce increased 
expression of CDCP1. Our 
immunohistochemical analysis of benign, 
primary and metastatic serous epithelial 
ovarian tumors demonstrates that CDCP1 is 
expressed during progression of this cancer. 
These data highlight a novel role for CDCP1 in 
EGF/EGFR-induced cell migration and 
indicate that targeting of CDCP1 may be a 
rational approach to inhibit progression of 
cancers driven by EGFR signaling including 
those resistant to anti-EGFR drugs because of 
activating mutations in the 
RAS/RAF/MEK/ERK pathway. 
 
Epidermal growth factor receptor (EGFR) is a 
receptor tyrosine kinase consisting of an 
extracellular ligand-binding domain, a membrane 
spanning region and a cytoplasmic tail containing 
a kinase domain and docking sites for signaling 
effectors and modulators (1, 2). Ligand mediated 
activation of EGFR requires binding, by one of at 
least six growth factors including epidermal 
growth factor (EGF), to the receptor extracellular 
domain (3, 4) which initiates autophosphorylation 
of specific receptor cytoplasmic tyrosine residues, 
including tyrosine 1068 (Y1068) (5). This triggers 
further signaling events, including activation of 
RAS/RAF/MEK/ERK (6, 7) and Src family kinase 
(SFK) (8-13) pathways, that promote a range of 
cellular processes including migration (14-16).  
 
As with other mediators of migration, EGFR 
activation alters cellular plasticity to promote the 
transition from a morphology where cells are in 
intimate contact with neighbors and substratum, to 
an elongated, spindle shape associated with 
increased ability to migrate and invade into 
surrounding matrix (17-19). In a range of cell 
lines EGF/EGFR-mediated migration is 
accompanied by a so-called epithelial to 
mesenchymal transition (EMT) involving loss of 
expression of proteins necessary for maintenance 
of epithelial phenotypes, such as E-cadherin  (20, 
21), as well as augmented expression of proteins 
associated with mesenchymal phenotypes 
including N-cadherin (18, 22) and vimentin (23).  
 
In physiological settings EGFR-mediated cell 
migration is tightly regulated to mediate normal 
development and homeostasis (24). However, in 
disease states, such as cancer, elevated EGFR 
signaling, either via activating mutations or 
increased expression, promotes aberrant cell 
migration. Interestingly, although this 
inappropriate activation of EGFR is a known 
promoter of malignancies of the lung, colon, 
pancreas, breast, head and neck and ovary (25) 
and targeting this receptor has shown much 
promise in preclinical settings, anti-EGFR drugs 
have been largely ineffective for the treatment of 
each of these cancers except non-small cell lung 
cancer (25, 26). The lack of efficacy of EGFR 
inhibition alone is due in part to drug resistance 
resulting from mutations in downstream signaling 
effectors such as RAS and RAF, or activation of 
other receptors including IGF-1R and Met (25, 
26).  
 
Recently the cell surface glycoprotein CUB 
domain containing protein 1 (CDCP1, also named 
SIMA135, gp140, Trask and CD318 (27-30)) has 
emerged as a promoter of cell migration in vitro 
and cancer cell dissemination in animal models 
(31, 32). For example, CDCP1 promotes in vitro 
migration and peritoneal dissemination of 
scirrhous gastric carcinoma cell lines (33) as well 
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as in vitro migration of pancreatic cancer cells 
(34). In addition, antibody targeting of CDCP1 
inhibits prostate cancer cell migration and 
invasion in vitro and metastasis in a mouse 
xenograft model (35). Antibody based disruption 
of CDCP1 function has also been effective at 
blocking in vivo dissemination of a highly 
metastatic prostate cancer PC3 cell variant and 
HeLa and HEK293 cells ectopically expressing 
CDCP1 (36, 37). The mechanisms regulating 
CDCP1 in cell migration have been largely 
unexplored although recently this protein was 
shown to be regulated by hypoxia-inducible factor 
(HIF) 1α and 2α and to play a critical role in 
kidney cancer cell migration (38). 
 
In this study we have used EGF/EGFR responsive 
epithelial ovarian cancer cell lines to explore the 
role of CDCP1 in EGFR-induced cell migration. 
We demonstrate that CDCP1 mRNA expression is 
upregulated by EGF/EGFR signaling via a 
pathway that involves the activity of ERK but not 
Src. We also show that antibody and shRNA-
mediated disruption of CDCP1 efficiently block 
EGF/EGFR-induced cell migration. Our 
immunohistochemical analysis demonstrates that 
CDCP1 is expressed during ovarian cancer 
progression. Targeting of CDCP1 may be a 
rational approach to inhibit malignancies, such as 
ovarian cancer, that are driven by EGF/EGFR. 
 
EXPERIMENTAL PROCEDURES 
Antibodies and reagents–Antibodies were from 
the following suppliers: rabbit polyclonal antibody 
against unspecified C-terminal residues of CDCP1 
(#4115 used in Western blot and 
immunohistochemical analyses), rabbit anti-
pEGFR-Y1068, mouse anti-EGFR, rabbit anti-
pSrc-Y416, mouse anti-Src, mouse anti-
pMAPK/p44/42 (pERK1/2-Y202/204) and rabbit 
anti-ERK1/2 (Cell Signaling Technology, 
Quantum Scientific, Murarrie, Australia); 
monoclonal anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibody and anti-
mouse immunoglobulin (IgG) from Sigma (Castle 
Hill, Australia); monoclonal anti-E-cadherin and 
anti-N-cadherin antibodies and goat anti-mouse 
Alexa Fluor 488 antibody (Invitrogen, Mount 
Waverley, Australia); IRDye 680 or 800 
conjugated mouse or rabbit IgG (LI-COR 
Biosciences, Lincoln, NE, USA); anti-CDCP1 
monoclonal antibody 10D7 (used for confocal 
microscopy analysis and cell migration assays) 
was previously described (39). Alexa Fluor 568 
phalloidin and 4'-6-diamidino-2-phenylindole 
(DAPI) were from Invitrogen, and Complete 
EDTA-free protease inhibitor cocktail was from 
Roche Applied Sciences (Castle Hill, Australia). 
EGFR antagonist AG1478, SFK selective 
inhibitor SU6656 and ERK inhibitor U0126 were 
from Sigma. All other reagents were from Sigma 
except where noted.  
 
Cell lines, cell culture and treatment–The ovarian 
cancer cell lines OV90, Caov3 and SKOV-3, and 
a normal fibroblast cell line NFF1 were purchased 
from American Type Culture Collection 
(Manassas, VA). PEO1, PEO4, PEO14 and 
OAW42 epithelial ovarian cancer cell lines were 
described previously (40). OVCA420 and 
OVCA432 epithelial ovarian cancer cell lines (41) 
were kindly provided by Samuel Mok (University 
of Texas MD Anderson Cancer Center, Houston, 
TX). The OVMZ-6 cell line (42) was a kind gift 
from Viktor Magdolen (Technical University of 
Munich, Munich, Germany). All cell lines were 
cultured in RPMI 1640 media with 10% fetal calf 
serum (FCS) and penicillin (100 units/ml) and 
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streptomycin (100 units/ml) except for OVMZ-6 
which were cultured in DMEM containing 10% 
FCS, penicillin (100 units/ml) and streptomycin 
(100 units/ml), 2 mM sodium pyruvate and L-
glutamine (42). For treatments with 
pharmacological agents, cells were cultured until 
60% confluent then washed twice with PBS 
before growth in serum free media (SFM) for 24 h 
before treatment with 0.1% DMSO, 0.1% DMSO 
with EGF (30 ng/ml), or 0.1% DMSO with EGF 
(30 ng/ml) and AG1478 (20 µM), SU6656 (10 
µM) or U0126 (10 µM) for 0.2 and 24 h. For 
antibody treatments, cells were cultured as above 
followed by treatment with control IgG (20 
µg/ml), EGF (30 ng/ml) and control IgG, or EGF 
(30 ng/ml) and CDCP1 function blocking 
antibody 10D7 (20 µg/ml).  
 
RNA extraction and quantitative reverse 
transcription-PCR (RT-PCR)–Total RNA 
extraction and cDNA synthesis were performed as 
described previously (43). Briefly, total RNA was 
extracted using Trizol reagent (Invitrogen) 
followed by treatment with DNase I (Invitrogen), 
and 2 µg RNA was reverse-transcribed using a 
Superscript III reverse transcriptase kit 
(Invitrogen). Quantitative-RT-PCR was 
performed on a Rotor-Gene cycler (Qiagen, 
Doncaster, Australia) with CDCP1 specific 
primers 5´-
AATCTACGTGGTTGACTTGAGTAA-3´ and 
5´-CCACATTCATCCACAGACG-3´ 
incorporating SYBR green (Takara, Tokyo, 
Japan). CDCP1 expression was normalized to 
HPRT1 (primers: forward, 5´- 
TGAACGTCTTGCTCGAGATGTG-3´ and 
reverse, 5´-CCAGCAGGTCAGCAAAGAATTT-
3´). The ΔCT method (44) was used to determine 
fold change from 3 separate experiments with 
triplicate wells per experiment.  
 
Cell lysis and Western blot analysis–Whole cell 
lysates were collected in a buffer containing 
Complete protease inhibitor cocktail (1×), 2 mM 
sodium vanadate, 10 mM sodium fluoride, 50 mM 
Tris-HCl (pH 7.4), NaCl (150 mM) and CHAPS 
(1%). Protein concentration was determined by 
microbicinchoninic acid assay (Thermo 
Scientific). Cell lysates (20 µg) were separated by 
SDS-PAGE under reducing conditions, transferred 
to nitrocellulose membranes, and blocked in 
Odyssey blocking buffer (LI-COR® Biosciences). 
Membranes were incubated with primary 
antibodies diluted in blocking buffer overnight at 
4ºC, washed with tris-buffered saline containing 
0.05% Tween-20, and then incubated with 
secondary IRDye 680 or 800 conjugated mouse or 
rabbit IgG as appropriate. Images were generated 
and densitometry analysis was performed using 
the Odyssey system and software (LI-COR 
Biosciences).  
 
Phase contrast and time-lapse images–Bright 
field images were captured using a phase contrast 
microscope and a digital camera (10 × objective, 
Nikon Eclipse TE2000-U, Nikon, Japan) and V++ 
software. Time lapse images were captured every 
15 min up to 24 h using a Leica AF-1600 wide-
field microscope and system software (Leica 
Microsystems, Sydney, Australia). Cell scattering 
was measured as the distance between cell nuclei 
in 3 independent experiments using InDesign 
software (Adobe, Adobe Systems Pty Ltd, 
Chatswood, Australia). For cells silenced for 
CDCP1, measurements were performed from 
images acquired from the Nikon Eclipse system 
on 200 pairs of cells from 10 randomly selected 
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fields per treatment group. For cells treated with 
anti-CDCP1 antibody 10D7 or control IgG, 
measurements were performed from time lapse 
images acquired on the Leica AF-1600 system on 
at least 80 individual randomly selected cells per 
treatment group. 
 
Confocal microscopy analysis–Cells were grown 
in serum containing media on sterile cover-slips 
until 60% confluent. The cells were then grown in 
serum free media for a further 24 h then either left 
untreated or treated with EGF (30 ng/ml) for 24 h. 
After washes with PBS, cells were fixed (4% 
(w/v) paraformaldehyde in PBS), permeabilized 
(0.5% (v/v) Triton X-100 in PBS) and blocked 
(5% (w/v) BSA in PBS) then incubated with 
mouse monoclonal anti-CDCP1  antibody 10D7 
(dilution 1:200 (v/v) in 1% BSA/PBS) at room 
temperature for 2 h. After washes, cells were 
incubated with a mouse Alexa Fluor 488 
conjugated secondary antibody, Alexa Fluor 568 
phalloidin and DAPI. Images were acquired using 
a Leica-TCS SP5 confocal microscope (63 × oil 
immersion objective lens). 
 
Lentiviral shRNA gene silencing–CDCP1 
expression was suppressed as previously 
described (45). Briefly, to generate lentivirus a 
CDCP1 pLKO.1 lentiviral shRNA knock-down 
construct (OpenBiosystems, Millennium Science, 
Surrey Hills, Australia) or a control scramble 
shRNA construct (Addgene, Cambridge, MA) was 
transfected into HEK293T cells together with 
packaging plasmids (pCMV-VSVG and pCMV-
dR8.2-dvpr) using Lipofectamine 2000 
(Invitrogen). Filtered conditioned media was used 
to sequentially infect target cells in the presence 
of 8 µg/ml of hexadimethrine bromide. Polyclonal 
pools of stably infected cells were selected in 
puromycin (2 µg/ml) containing medium for 1 
week.  
 
Immunohistochemistry–Paraffin-embedded tissue 
sections (4 µm) were from benign serous 
adenomas (n = 3), primary serous tumors (n = 3) 
and serous metastases (n = 3). The source of these 
tissues was described previously (43) and each 
was used with institutional ethics approval 
(Queensland University of Technology certificate 
no. 080000213) and informed patient consent. 
Immunohistochemistry was performed as 
previously described (40). Briefly, sections (4 μm) 
were deparaffinized in xylene and rehydrated 
followed by antigen retrieval with microwave heat 
treatment in 10 mM citric acid (pH 6.0). Sections 
were incubated overnight at 4°C with a rabbit 
anti-CDCP1-C-terminal antibody (1:100 in 1% 
(w/v) BSA in PBS) or rabbit IgG as negative 
control (Dako, Campbellfield, Australia). Signal 
was detected using the EnVisionTM peroxidase 
system (Dako) and sections were counterstained 
with Gill’s hematoxylin. Staining was visualized 
using an Olympus BX41 microscope (Olympus, 
Japan) and photographed with a Qimaging digital 
camera (MicroPublisher 3.3RTV) and associated 
software (QCapture Pro 6.0, Burnaby BC, 
Canada). Images were processed using Adobe 
Photoshop CS3 and displayed using CorelDraw14 
(Corel Pty Ltd, Sydney, Australia). 
 
Statistical analysis–One-tailed Student’s t-tests 
were performed for statistical analysis. P values 
with a 95% confidence interval were obtained 
from at least 3 independent experiments using 
GraphPad Prism (GraphPad Software, Inc, La 
Jolla, CA). A P value < 0.05 was considered to be 
significant.  
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RESULTS  
CDCP1 is upregulated by the EGF/EGFR 
signaling axis–To identify cell lines suitable for 
examination of the role of CDCP1 in EGF/EGFR-
mediated cell migration, we first analyzed the 
expression of CDCP1 in 10 epithelial ovarian 
cancer derived cell lines. Anti-CDCP1 Western 
blot analysis was performed on lysates from cells 
cultured in serum containing media. CDCP1 is 
produced as a 135 kDa cell surface protein (28) 
that is proteolytically processed in a range of 
cultured cell lines (29, 44) as well as in in vivo 
settings (29, 37) to a 70 kDa cell retained form. 
As shown in Figure 1A, 70 and 135 kDa CDCP1 
species were most highly expressed by OVCA420 
cells with high relative expression of these species 
also apparent in OVCA432, PEO1 and PEO4 
cells. Lower level expression of both bands was 
also apparent in OV90 and PEO14 cells while the 
135 kDa band was apparent in OAW42 and 
SKOV-3 cells (Fig 1A). Caov3 cells expressed the 
135 kDa band at high levels with much lower 
levels of 70 kDa CDCP1 generated by this cell 
line. OVMZ-6 cells were the only ovarian cancer 
line that did not express CDCP1.  
 
A subset of the CDCP1 expressing cell lines 
(Caov3, OVCA420, OVCA432, PEO4) were next 
evaluated for the ability to respond to EGF 
stimulation. This was performed by Western blot 
analysis for phosphorylated EGFR-Y1068, a site 
that is phosphorylated by Jak2 to provide a 
docking site for Grb2 and activation of MAP 
kinases (46). In this and all subsequent 
experiments the effects of EGF stimulation were 
maximised by growth of cell lines in serum free 
media for 24 h before EGF stimulation. As shown 
in Figure 1B, EGF induced rapid phosphorylation 
of EGFR in each cell line and this was sustained 
for at least 1 h.  
 
The effect of EGF signaling on CDCP1 
expression was analyzed at mRNA and protein 
levels in two of the EGF responsive cell lines, 
Caov3 and OVCA420. Quantitative real-time RT-
PCR analysis was performed on total RNA 
isolated from cells treated with EGF for 0.2 and 
24 h. As shown in Figure 2A, while EGF had no 
effect on CDCP1 mRNA levels at 0.2 h, it 
induced a greater than 2 fold increase in 
expression in both cell lines at 24 h.  
 
Consistent data showing EGF-induced 
upregulation of CDCP1 were obtained at the 
protein level. In these experiments cells were 
serum starved for 24 h then stimulated with EGF 
for 0.1, 0.2, 0.5, 1, 8 and 24 h. In control 
experiments cells were treated with the potent and 
selective EGFR inhibitor AG1478 (47). As shown 
in Figure 2B (left), EGF induced an 
approximately 2.5 fold increase in expression of 
135 kDa CDCP1 in Caov3 cells within 1 h and 
this was sustained up to 24 h. AG1478 treatment 
blocked this induction indicating that EGF-
induced upregulation of CDCP1 was mediated by 
EGFR. In contrast with OVCA420 cells grown in 
serum containing media, which generated 
abundant levels of 70 kDa CDCP1 (Fig 1A), these 
cells grown in serum free media expressed very 
low levels of this species and like the Caov3 line, 
70 kDa CDCP1 was not induced by EGF (Fig 
2B). While it is clear that CDCP1 can undergo 
proteolytic conversion from 135 to 70 kDa in a 
range of cultured cells (44), the identity of the 
protease responsible for cleavage of CDCP1 in 
these lines has not been determined. This is in 
contrast with proteolytic processing of CDCP1 
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that occurs during metastasis in vivo which has 
recently been shown to be mediated in mice by 
plasmin (37). We propose that because not all cell 
lines that express 135 kDa CDCP1 also generate 
70 kDa CDCP1 when grown in serum containing 
media (Fig 1A; OAW42 and SKOV-3 cells), 
either CDCP1 cleaving cell lines produce a 
protease that activates a latent protease present in 
serum that cleaves CDCP1, or these cell lines 
produce a protease that directly cleaves CDCP1. 
Based on comparison of the data for Caov3 and 
OVCA420 cells in Figure 1A (serum containing 
media) and 2B (serum free media +/- EGF), we 
suggest that EGF does not induce cleavage of 
CDCP1 via induction of either a protease that 
directly cleaves CDCP1 or a protease that 
activates a CDCP1 cleaving protease present in 
serum that has remained associated with the cells 
in serum free conditions. In addition, we also note 
from Figure 2B that there was no change in 
expression of the EMT markers E-cadherin (21) 
and N-cadherin (22) in response to EGF.  
 
ERK signaling is required for EGF/EGFR-
mediated upregulation of CDCP1–We also 
examined whether two known EGF/EGFR 
activated pathways are required for the observed 
increased expression of CDCP1. We first assessed 
whether these pathways (ERK (15, 16) and Src (8-
13)) are activated downstream of EGF/EGFR in 
the two lines used in this study, Caov3 and 
OVCA420 cells. Western blot analysis showed 
that ERK (phosphorylation of T202/Y204) is 
rapidly activated in both cell lines in response to 
EGF and phosphorylation of this protein reduced 
gradually 8 to 24 h after initial stimulation (Fig 
3A). In contrast, activation of Src 
(phosphorylation of Y416) paralleled the increases 
in CDCP1 expression seen in Figure 2B with 
increasing pSrc levels apparent after 0.5 h of EGF 
treatment and this was sustained up to 24 h (Fig 
3A). In these experiments AG1478 treatment 
blocked phosphorylation of ERK and Src 
demonstrating that EGF-induced activation of 
these kinases was mediated by EGFR (Fig 3A). 
These data indicate that both ovarian cancer cell 
lines signal similarly in response to EGF/EGFR 
via ERK and Src.  
 
Using selective pharmacological agents we 
examined if antagonism of these pathways affects 
EGF/EGFR-induced upregulation of CDCP1. 
Activation of ERK was inhibited with U0126 (48) 
and SFK activation with SU6656 (49). Inhibition 
of EGF/EGFR-induced expression of CDCP1 was 
quantified by densitometric analysis of Western 
blots of 3 independent experiments. This showed 
that the ~2 fold increase in CDCP1 expression 
induced by EGF in Caov3 and OVCA420 cells 
was reduced to background levels by U0126 
inhibition of ERK (Fig 3B). In contrast, the SFK 
inhibitor SU6656 caused a 100% increase in 
CDCP1 expression above the effect of EGF in 
Caov3 cells and had no impact on its expression in 
OVCA420 cells (Fig 3B). EGF treatment in the 
presence of vehicle (0.1% DMSO) was used as 
positive control for upregulation of CDCP1 (Fig 
3B). These data indicate that EGF/EGFR 
upregulation of CDCP1 requires signalling via the 
RAS/RAF/MEK/ERK pathway but not via SFKs. 
 
EGF/EGFR signaling induces cell migration and 
relocalization of CDCP1–The effect of 
EGF/EGFR signaling on cell migration and 
localization of CDCP1 was examined by 
microscopy. As shown in Figure 4Aa-b, 
unstimulated and vehicle treated (0.1% DMSO) 
Caov3 cells grow as defined colonies. In response 
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to 24 h of EGF stimulation these cells acquire a 
spindle shaped morphology and migrate as 
evidenced by cell scattering (Fig 4Ac). Pre-
treatment of Caov3 cells with the EGFR inhibitor 
AG1478 blocked both the transition to a spindle 
shaped morphology and cell scattering 
demonstrating that EGF-induced changes were 
mediated by EGFR (Fig 4Ad). OVCA420 cells, 
which grow as colonies that are less clearly 
defined than Caov3 cell colonies, also acquired a 
spindle shaped morphology and underwent cell 
scattering in response to EGF which was blocked 
by antagonism of EGFR (Fig 4Ae-h).  
 
To examine the effect of EGF on the cellular 
localization of CDCP1, we performed confocal 
microscopy on unstimulated and EGF stimulated 
Caov3 and OVCA420 cells staining for CDCP1 
(green), F-actin (red) and cell nuclei (blue). In 
unstimulated Caov3 and OVCA420 cells CDCP1 
was largely restricted to the cell membrane at cell-
cell contacts where it co-localized with F-actin 
(Fig 4Ba, b, e, f; yellow). However, 24 h after 
EGF treatment, intense punctuate CDCP1 staining 
was seen in the cytoplasm and also on the outside 
of the F-actin boundary of cells along filopodia 
that developed in response to EGF (Fig 4Bc, d, g, 
h; green). The relocalization of CDCP1 from cell-
cell junctions to filopodia is consistent with this 
protein having a function in EGF-induced cell 
migration. 
 
Disruption of CDCP1 expression and function 
reduces EGF-induced cell morphology changes 
and migration–Two approaches were employed to 
directly address the role of CDCP1 in EGF-
induced cell migration. First, we interfered with 
the up-regulation of CDCP1 expression induced 
by EGF. Second, we disrupted CDCP1 function 
using a previously characterized monoclonal anti-
CDCP1 antibody, 10D7, that blocks the ability of 
cancer cells to disseminate in chicken embryo and 
mouse models of metastasis (36, 37). 
 
To interfere with EGF-induced upregulation of 
CDCP1, we generated polyclonal pools of Caov3 
and OVCA420 cells stably infected with either a 
CDCP1 shRNA construct or a scramble control 
construct. The CDCP1 shRNA construct 
abolished CDCP1 expression in both Caov3 and 
OVCA420 cells compared to scramble controls 
and blocked the ability of EGF to induce, 
compared to the scramble control, upregulation of 
CDCP1 at both 0.2 and 24 h (Fig 5A). 
Microscopy analysis indicated that loss of CDCP1 
had little impact on Caov3 and OVCA420 cell 
morphology (Fig 5B, -EGF, compare Scramble 
with shCDCP1). However, silencing of this 
protein reduced the ability of these cells to 
migrate and acquire an EGF-induced elongated 
spindle shaped morphology including the 
acquisition of filopodia (Fig 5B, +EGF, compare 
Scramble with shCDCP1). This qualitative 
analysis was confirmed by quantitative analysis of 
the distance between cells in 3 independent 
experiments which showed that silencing of 
CDCP1 blocked Caov3 and OCA420 cell 
migration induced by EGF (Fig 5C). These data 
suggest that the role of CDCP1 in EGF/EGFR-
induced ovarian cancer cell morphological 
changes and increased migration requires its 
upregulation at the transcriptional level.  
 
In experiments to assess the effect of blockade of 
CDCP1 function on EGF/EGFR-induced cell 
migration, Caov3 and OVCA420 cells in the 
presence and absence of the anti-CDCP1 antibody 
10D7 were imaged by time-lapse microscopy, 
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collecting images every 15 min up to 12 h for 
OVCA420 cells and 24 h for Caov3 cells. 
Consistent with data in Figure 4A, images from 
time-lapse microscopy demonstrated that EGF 
treatment in the presence of control IgG induces a 
spindle shaped morphology and cell scattering in 
both cell lines (Fig 6A and B, IgG+EGF). These 
changes were inhibited by concomitant treatment 
with 10D7 consistent with a role for CDCP1 in 
EGF/EGFR-induced cell migration (Fig 6A and 
B). In Caov3 cells antibody blockade of cell 
morphological changes and migration was first 
apparent approximately 8 h after commencement 
of EGF treatment (Fig 6A, 10D7+EGF, 8 h). 
Quantitative analysis of at least 80 cells per 
treatment group showed that at 24 h EGF in the 
presence of IgG induced an increase of ~15 fold in 
migration over IgG only and this was decreased to 
an ~8 fold increase by 10D7 treatment (Fig 6A, 
graph). In OVCA420 cells blockade was first 
apparent about 4 h after commencement of EGF 
treatment (Fig 6B, 10D7+EGF, 4 h). Quantitative 
analysis of at least 80 cells per treatment group 
showed that at 12 h EGF treatment in the presence 
of IgG induced an increase of ~16 fold in 
migration over IgG only and this was decreased to 
an ~6 fold increase by 10D7 treatment (Fig 6B, 
graph). These data support a functional role for 
CDCP1 in the morphological changes and 
increased migration of ovarian cancer Caov3 and 
OVCA420 cells induced by EGF/EGFR.  
 
CDCP1 is expressed by primary and metastatic 
ovarian tumors–To examine whether CDCP1 is 
expressed in ovarian cancer we performed 
immunohistochemical analysis on a series of 
ovarian cancers representing the progression from 
benign to malignant to metastatic disease 
including benign tumors from 3 patients, primary 
serous epithelial ovarian cancers from 3 patients 
and metastases from 3 patients. Representative 
images of anti-CDCP1 antibody and control 
staining are shown in Figure 7. Little expression 
of CDCP1 was seen in the 3 benign serous 
adenomas, while higher levels of CDCP1 staining 
was seen in primary (P) well differentiated (Grade 
1) serous tumors (compare Fig 7A-B and 7C-D). 
The most intense CDCP1 staining was seen in the 
3 metastatic (M) ovarian tumors (Fig 7E-G), 
including intense plasma membrane and 
cytoplasmic staining apparent in two of these 
metastases (Fig 7E-F). No staining was seen in 
control slides in which the primary antibody was 
replaced with rabbit IgG (Fig 7H). These data 
indicate that CDCP1 is expressed in epithelial 
ovarian tumors. A larger sample size is required to 
examine whether changes in expression of 
CDCP1 occur consistently during progression 
from adenoma to malignant ovarian cancer. 
 
DISCUSSION 
The EGF/EGFR axis has well studied roles in cell 
migration and cancer progression (25). Our data, 
which are summarized in Figure 8, define a new 
mechanism, involving the cell surface 
glycoprotein CDCP1, that regulates this cell 
migration signaling axis. We have demonstrated 
that disruption of CDCP1, either by silencing or 
the use of a function blocking antibody, 
substantially reduces the ability of EGF/EGFR to 
induce migration of ovarian cancer Caov3 and 
OVCA420 cells. Our data indicate that 
EGF/EGFR-induced cell migration is preceded by 
increased expression of CDCP1 and this increased 
expression is accompanied by relocalization of 
CDCP1 from cell-cell junctions to punctate 
structures on filopodia. Studies with 
pharmacological agents indicate that inhibition of 
 JBC
10 
 
ERK but not Src signaling blocks upregulation of 
CDCP1 indicating that the RAS/RAF/MEK/ERK 
pathway is required downstream of EGF/EGFR to 
induce increased expression of CDCP1. Our 
observation from immunohistochemical analysis 
that CDCP1 is expressed by epithelial ovarian 
tumors has potential implications for treatment of 
this and other malignancies driven by EGF/EGFR 
signaling. In particular, it is possible that 
disruption of CDCP1 function may be a useful 
approach to limit the dissemination of cancer cells 
in vivo, including ovarian, lung and colorectal 
cancer cells, that are resistant to anti-EGFR 
therapies due to activating mutations in 
downstream signaling effectors such as RAS and 
RAF (25, 26, 50). It will be important to perform 
further analyses of larger patient cohorts to 
examine how CDCP1 expression alters with 
changes in expression and/or mutation of EGFR 
pathway components and whether targeting of 
CDCP1 represents a rational approach to treat 
these cancers.   
 
EGF/EGFR regulation of CDCP1 is the third 
reported CDCP1 regulating pathway. The other 
pathways are: (i) SFK phosphorylation and (ii) 
hypoxia. SFK phosphorylation of CDCP1 is 
important for cancer cell survival, migration and 
invasion in vitro and in vivo (33, 34, 37, 51-53) 
and is activated in at least 3 cellular settings: cell 
de-adhesion, increased serine protease activity and 
overexpression of CDCP1 (45). Mechanistically it 
involves SFK phosphorylation of CDCP1 at 
tyrosine (Y) 734, Y734 and Y762, coupling of 
PKCδ at this last phospho-tyrosine and reciprocal 
activation of phosphorylation of SFKs at Y416 
(34). Although we saw that pSrc-Y416 levels 
increased in parallel with the expression of 
CDCP1 induced by EGF/EGFR (compare Fig 3A 
and B with Fig 5A and B), we did not observe any 
change in phosphorylation of CDCP1-Y734 
during EGF/EGFR-induced cell migration (data 
not shown). This indicates that mechanistically 
EGF/EGFR-mediated cell migration does not 
require phosphorylation of CDCP1 and suggests 
that in ovarian cancer cells, and potentially other 
cancer lines, signaling via EGF/EGFR and SFKs 
represent distinct CDCP1 regulating pathways.  
 
In the second reported CDCP1 regulating pathway, 
expression of this protein is induced in kidney 
cancer cell lines by hypoxic conditions via a 
mechanism requiring the transcription factors 
HIF-1α and -2α (38). As EGFR is upstream of 
HIF signaling in prostate (54) and kidney (55) 
cancer cells it is possible that EGF/EGFR and HIF 
pathways may converge to regulate CDCP1 
function. These reports on SFK and HIF 
regulation of CDCP1 and the current work are 
beginning to shed light on mechanisms controlling 
CDCP1 function and highlight the potential 
complexity of these pathways. 
 
In our in vitro cell assays we were able to isolate 
EGF/EGFR regulated effects from other cellular 
modulators, such as proteolysis, by growing cells 
in serum free conditions. One of the interesting 
observations from these experiments was that 
there was no evidence of the 70 kDa CDCP1 
species previously shown to be generated from the 
135 kDa precursor protein by the in vitro action of 
serine proteases such as trypsin (31) and 
matriptase (32, 47) and in vivo by urokinase (31) 
and plasmin (39). However, in more complex 
cellular settings, such as serum containing in vitro 
cell culture and in animal models, EGF/EGFR 
regulation of CDCP1 will occur 
contemporaneously with other regulatory 
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mechanisms such as proteolysis and hypoxia. To 
understand how CDCP1 functions mechanistically 
to support EGF/EGFR-induced cell migration, we 
are currently exploring whether this pathway 
functions synergistically or in competition with 
serine protease and hypoxic regulation of CDCP1. 
 
EGF via its receptor activates downstream 
signaling pathways that modify the cytoskeleton 
and initiate transcriptional and post-transcriptional 
regulation leading to altered cell plasticity and 
increased cell migration (56). We have shown that 
this signaling pathway not only initiates 
upregulation of CDCP1 mRNA and protein via 
activation of ERK, it also results in relocalization 
of CDCP1 from cell-cell junctions to punctate 
structures along filopodia. We propose that it is 
this repositioning of CDCP1 that is essential for 
its role in EGF/EGFR-induced cell migration. Our 
antibody-mediated blockade of CDCP1 prevented 
it from fulfilling this critical migration promoting 
role on filopdia. It is worth noting that although 
this antibody, 10D7, blocked ovarian cancer cell 
migration it had no impact on cell survival (not 
shown) in contrast with data from in vivo systems 
where this antibody caused apoptosis of cells 
escaping from blood vessels (36, 37). This would 
suggest that the ability of this antibody to induce 
cell death via blockade of CDCP1 function is 
context dependent. In in vivo settings where 
CDCP1 is promoting cell survival, antibody 10D7 
blockade of this function induces cell death; 
however, in vitro this antibody blocks the role of 
CDCP1 in EGF/EGFR-induced cell migration 
without impacting on cell survival. This supports 
the proposal that the molecular mechanism 
regulating the role of CDCP1 in cell survival 
(SFK signaling) is distinct from the pathway 
promoting cell survival (EGF/EGFR signaling). 
 
Interestingly, although EGF/EGFR signalling 
clearly altered the plasticity of ovarian cancer 
Caov3 and OVCA420 cells, resulting in loss of 
cell contact with neighbors, elongation and 
scattering (Fig 4), this was not accompanied by 
changes in expression of markers associated with 
an EMT (Fig 2B). This contrasts with two other 
ovarian cancer lines, OVCA433 and SKOV-3 
cells, which undergo an EMT in response to 
EGF/EGFR activation as evidenced by changes in 
marker expression including decreased E-cadherin 
(21) and increased N-cadherin (22). EMT is 
thought to be required for the cell migration 
essential for a range of physiological processes as 
well as for progression of a number of cancers 
(57). However, the involvement of EMT in 
ovarian cancer is not clear because of the unique 
mixed epithelial and mesenchymal features of 
normal ovarian epithelium including low 
expression of the epithelial marker E-cadherin and 
expression of the mesenchymal markers keratin, 
vimentin and N-cadherin (17). In addition, 
analysis of patient samples indicates that in 
contrast with many other cancers, ovarian cancers 
express high levels of E-cadherin mRNA and 
protein (18, 58, 59). This lack of clarity on the 
role of EMT in ovarian cancer is also highlighted 
by cell line studies. For example, while some E-
cadherin expressing ovarian cancer cells can be 
invasive in vitro and in vivo (60, 61), loss of 
expression of this protein promotes invasiveness 
of other ovarian cancer cell lines (62). Our data 
indicate that disruption of CDCP1 blocks the 
EGF/EGFR-induced migration of two ovarian 
cancer cell lines that do not show altered 
expression of EMT markers. It will be interesting 
to examine whether blockade of this protein can 
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also reduce the EGF/EGFR-induced migration of 
ovarian cancer cells that do undergo EMT.  
 
In conclusion, these data highlight a novel role for 
the cell surface glycoprotein CDCP1 in 
EGF/EGFR-induced cell migration and indicate 
that targeting of CDCP1 may represent a rational 
approach to inhibit progression of cancers driven 
by this pathway.  
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FOOTNOTES 
The abbreviations used are: CDCP1, CUB-domain containing protein 1; DAPI, 4'-6-Diamidino-2-
phenylindole; EDTA, ethylene diamin tetra-acetic acid; FCS, fetal calf serum; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; IgG, immunoglobulin; SFK, Src family kinase. 
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FIGURE LEGENDS 
FIGURE 1. CDCP1 expression in ovarian cancer cell lines. A, Anti-CDCP1 and anti-GAPDH Western 
blot analysis of lysates from 10 ovarian cancer cell lines and normal foreskin fibroblasts (NFF) cultured in 
media containing 10% serum. The molecular weight of the CDCP1 bands at 70 and 135 kDa are indicated. 
B, Anti-pEGFR (Y1068) and anti-GAPDH Western blot analysis of lysates from Caov3, OVCA420, 
OVCA432 and PEO4 ovarian cancer cell lines cultured in serum free media either untreated or EGF 
treated (30 ng/ml in 0.1% DMSO) for the indicated times. 
 
FIGURE 2. CDCP1 is upregulated by EGF activation of EGFR. A, Graphical representation of fold 
change in CDCP1 mRNA levels relative to HPRT1 mRNA in response to EGF (30 ng/ml) in serum free 
media at 0.2 and 24 h. Bars represent fold change assessed using the ΔCT method. Data are mean ± SEM 
from 3 separate experiments with triplicate wells per experiment. B, Anti-CDCP1, -E-cadherin, -N-
cadherin and -GAPDH Western blot analysis of lysates from Caov3 cells. C, Anti-CDCP1, -E-cadherin, -
N-cadherin and -GAPDH Western blot analysis of lysates from OVCA420 cells. In B and C lysates were 
from cells grown in serum free media (lane 1), 0.1% DMSO (lane 2); 0.1% DMSO and EGF (30 ng/ml) 
for 0.1, 0.2, 0.5, 1, 8 and 24 h (lane 3-8); 0.1% DMSO, EGF (30 ng/ml) and AG1478 (20 µM) for 0.2 and 
24 h (lane 9-10). Graphical representation of densitometry analysis of anti-CDCP1 Western blot data 
from 3 independent experiments is shown below each panel. The ratio of the signal intensity of 135 kDa 
CDCP to GAPDH at each time point was normalized to the DMSO control.  
 
FIGURE 3. ERK signaling is required for EGF/EGFR mediated upregulation of CDCP1. A, Western 
blot analysis of pSrc-Y416 and Src, pERK1/2-Y202/204 and ERK1/2, pEGFR-Y1068 and EGFR in 
Caov3 (left) and OVCA420 (right) ovarian cancer cells. GAPDH was used as a loading control. Cells 
were grown in serum free culture media (lane 1), 0.1% DMSO (lane 2); 0.1% DMSO and EGF (30 ng/ml) 
for 0.1, 0.2, 0.5, 1, 8 and 24 h (lane 3-8); 0.1% DMSO, EGF (30 ng/ml) and AG1478 (20 µM) for 0.2 and 
24 h (lane 9-10). These data are representative of 3 independent experiments. B, Graphical representation 
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of densitometry analysis of 3 independent anti-CDCP1 Western blot analyses. Caov3 and OVCA420 cells 
were treated for 0.2 and 24 h with 0.1% DMSO; EGF (30 ng/ml) and 0.1% DMSO; EGF (30 ng/ml), 
0.1% DMSO and SU6656 (10 μM); or EGF (30 ng/ml), 0.1% DMSO and U0126 (10 μM). Values were 
obtained from the intensity of the 135 kDa CDCP1 band, normalized to GAPDH, relative to the untreated 
control. Statistical significance was examined using a Student’s t-test; * p < 0.05. 
 
FIGURE 4. Relocalization of CDCP1 during EGF/EGFR-induced cell migration. A, Phase contrast 
microscopy showing morphology of Caov3 and OVCA420 cells grown in serum free media and either 
untreated (a, e), or treated with 0.1% DMSO (b, f), 0.1% DMSO with EGF (30 ng/ml) (c, g) or 0.1% 
DMSO with EGF (30 ng/ml) and AG1478 (20 µM) (d, h) for 24 h. Data are representative of at least 3 
independent experiments. Bar, 100 µm. B, Confocal microscopy analysis of Caov3 and OVCA420 cells 
either untreated (a, b, e, f) or treated with 0.1% DMSO with EGF (30 ng/ml) (c, d, g, h) for 24 h. Cells 
were stained with anti-CDCP1 antibody 10D7 followed by a fluorescently labeled anti-mouse secondary 
antibody (green), AlexaFluor 568 phalloidin to stain F-actin (red) and DAPI to stain cell nuclei (blue). 
Scale bars are as indicated. 
 
FIGURE 5. Upregulation of CDCP1 mRNA is required for EGF-induced cell migration. A, Western 
blot analysis of CDCP1 and GAPDH expression in Caov3 and OVCA420 cells stably transfected with 
either a scramble control (Scramble) or CDCP1 pLKO.1 lentiviral shRNA (shCDCP1). Cells were either 
untreated (-) or treated with EGF (30 ng/ml in 0.1% DMSO) for 0.2 and 24 h in serum free media. B, 
Representative phase contrast microscopy images of scramble and shCDCP1 Caov3 and OVCA420 cells 
+/- EGF (30 ng/ml in 0.1% DMSO) for 24 h. C, Graphical representation of the effect of CDCP1 
silencing on cell migration induced by EGF. Migration at 2 and 24 h was assessed as the distance between 
cell nuclei in 3 independent experiments using InDesign software (Adobe, Adobe Systems Pty Ltd, 
Chatswood, Australia). Measurements were performed on 200 pairs of cells from 10 randomly selected 
fields per treatment group. Statistical significance was examined using a Student’s t-test; * p < 0.05, ** p 
< 0.01, *** p < 0.001. Scale bar, 50 μm. 
 
FIGURE 6. Antibody blockade of CDCP1 reduces EGF-induced cell morphology changes and 
increased migration Representative time lapse phase contrast microscopy images showing morphology 
and scattering of cells treated with either mouse IgG (20 µg/ml) as a control, EGF (30 ng/ml) and mouse 
IgG, or EGF (30 ng/ml) and CDCP1 function blocking antibody 10D7 (20 µg/ml) in serum free media. A, 
Caov3 cells. Representative images from 0, 8, 16 and 24 h are shown. B, OVCA420 cells. Representative 
images from 0, 4, 8 and 12 h are shown. On the right of each panel is the graphical representation of 
accumulated migration distance at 24 h for Caov3 cells and at 12 h for OVCA420 cells. The distance 
between cell nuclei was determined for at least 80 randomly selected cells for each treatment using 
MetaMorph Software Version 7.0.3 (Molecular Devices, Bio-Strategy, Hawthorne East, Australia). 
Statistical significance was evaluated using a Student’s t-test. *, p < 0.05; **, p < 0.01. Scale bar, 50 μm. 
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FIGURE 7. CDCP1 is expressed during progression of epithelial ovarian cancer. Tissue sections from 
3 benign serous ovarian adenomas, 3 primary serous epithelial ovarian cancers and 3 ovarian cancer 
metastases were stained with a rabbit anti-CDCP1 antibody or control rabbit IgG followed by a horse-
radish peroxidase conjugated secondary antibody. Positive CDCP1 signal appears as brown coloration. 
Representative images are shown. A-B, Benign serous adenoma. C-D, Well differentiated serous epithelial 
ovarian cancer from a primary (P) tumor. E-G, Poorly differentiated serous epithelial ovarian cancer 
metastases (M) to the omentum. H, Negative control where rabbit IgG replaced the primary antibody. 
Tumor grade is indicated above the relevant panel. Scale bar, 50 μm. 
 
FIGURE 8. Schematic representation of pathways required for the role of CDCP1 in EGF/EGFR-
induced cell morphological changes and increased cell migration. CDCP1 mediates, at least in part, 
EGF/EGFR-induced cell morphological changes and increased migration. EGF signals via EGFR (as 
indicated through use of the EGFR antagonist AG1478) to induce signaling via ERK that leads to 
upregulation of CDCP1 mRNA and protein. Targeting of CDCP1, either via silencing of its mRNA or 
through use of an anti-CDCP1 function blocking antibody, is effective at reducing these EGF-induced 
effects. Approaches that disrupt CDCP1 function may be useful to inhibit progression of malignancies 
driven by EGFR signaling, such as ovarian cancer, and those resistant to anti-EGFR drugs because of 
activating mutations in the RAS/RAF/MEK/ERK pathway.  
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